The Philadelphia Science Festival Carnival tents have all been folded and hauled away. There have already been four nights of non-stop science cafes at local watering holes. But, there are still six more days of the festival to go, and Penn Medicine faculty will be participating at events on most of those days.
In a layer cake of research labs nestled on separate floors in a remote corner of the Hospital of the University of Pennsylvania, a new use for an existing drug was uncovered. The drug, epothilone D (EpoD), stalled after original tests as a cancer treatment, but Perelman School of Medicine...
With this year’s Super Bowl setting a record for being the most-viewed show in U.S. television history, concussions – more technically, mild traumatic brain injury (TBI) – have probably been on many a mind this week. TBI has long been a leading cause of death and disability, with over 1.7 million cases in the US alone each year.
“A Culture of Collegiality”: Research Collaboration Leads to Stronger Outcome for Basic Science of Schizophrenia
Research from the Department of Psychiatry could have ended up as four or five different interesting papers with moderate impact in the field. Instead, we were able to tell a complete story by linking potential genetic risk factors of schizophrenia to a functional disruption in how the brain responds to sound. We then linked those processes together by identifying reduced activity in special nerve cells that are designed to make other cells in the brain work together at a very fast pace.
Tucked away in two separate labs at the Department of Psychiatry at Penn Medicine, researchers have spent more than a decade researching and testing a new treatment for depression. The drug became the first new medicine to treat depression in more than a decade when it received FDA approval in January.